Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials

Set Alert for Clinical Trials

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

ASCO Clinical Trials

Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

Clinical Trials Coronavirus COVID-19

Next Generation SERDs Progress In Breast Cancer; Standing Out In The Crowd Won't Be Easy

The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.

ASCO Clinical Trials

AstraZeneca Links With Accent To Target RNA-Modifying Proteins

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Clinical Trials Companies

Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa

Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.

Cancer ASCO

First Drugs For Lupus Nephritis Are Headed For US FDA Review

Two drugs that would be the first for lupus nephritis are on the doorstep of the US FDA, a novel drug voclosporin from Aurinia Pharmaceuticals and Benlysta from GlaxoSmithKline.

Clinical Trials Immune Disorders

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

ASCO Clinical Trials

BMS's Zeposia Shines in Ulcerative Colitis Phase III Study

BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.

Clinical Trials Gastrointestinal

ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.

ASCO Clinical Trials
See All
UsernamePublicRestriction

Register